120 related articles for article (PubMed ID: 11112084)
1. Assessment of health-related quality-of-life in patients after heart transplantation under therapy with tacrolimus or cyclosporine.
von Steinbüchel N; Limm H; Leopold C; Carr D
Transpl Int; 2000; 13 Suppl 1():S609-14. PubMed ID: 11112084
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-microemulsion.
Reimer J; Franke GH; Philipp T; Heemann U
Clin Transplant; 2002 Feb; 16(1):48-54. PubMed ID: 11982615
[TBL] [Abstract][Full Text] [Related]
3. Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine.
Kobashigawa JA
Transplant Proc; 1998 Jun; 30(4):1095-7. PubMed ID: 9636445
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients.
Undre NA; Meiser BM; Uberfuhr P; Reichart B; Stevenson P; Schäfer A; Möller A
Transplant Proc; 1998 Jun; 30(4):1112-5. PubMed ID: 9636451
[No Abstract] [Full Text] [Related]
5. The first report from the patient outcomes registry for transplant effects on life (PORTEL): differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens.
Hathaway D; Winsett R; Prendergast M; Subaiya I
Clin Transplant; 2003 Jun; 17(3):183-94. PubMed ID: 12780666
[TBL] [Abstract][Full Text] [Related]
6. Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.
Tsamandas AC; Pham SM; Seaberg EC; Pappo O; Kormos RL; Kawai A; Griffith BP; Zeevi A; Duquesnoy R; Fung JJ; Starzl TE; Demetris AJ
J Heart Lung Transplant; 1997 Jul; 16(7):723-34. PubMed ID: 9257254
[TBL] [Abstract][Full Text] [Related]
7. Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation.
Dew MA; Harris RC; Simmons RG; Roth LH; Armitage JM; Griffith BP
Transplant Proc; 1991 Dec; 23(6):3061-4. PubMed ID: 1721360
[No Abstract] [Full Text] [Related]
8. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
Herzberg GZ; Rossi AF; Courtney M; Gelb BD
J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
[TBL] [Abstract][Full Text] [Related]
9. Glucose metabolism in heart transplant recipients treated with FK506 or cyclosporine.
Sahar G; Berman M; Ben-Gal T; Sahar E; Kogan A; Michowitch R; Saute M; Kramer M; Sagie A; Shapira Y; Aravot D; Vidne BA
Transplant Proc; 2003 Mar; 35(2):678. PubMed ID: 12644092
[No Abstract] [Full Text] [Related]
10. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
Pirsch JD; Miller J; Deierhoi MH; Vincenti F; Filo RS
Transplantation; 1997 Apr; 63(7):977-83. PubMed ID: 9112351
[TBL] [Abstract][Full Text] [Related]
11. The impact of tacrolimus as rescue therapy in children using a double immunosuppressive regimen after heart transplantation.
Branco KC; Azeka E; Trindade E; Galas FR; Hajjar LA; Benvenuti L; Riso A; Tanamati C; Penha J; Auler JO; Jatene M
Transplant Proc; 2012 Oct; 44(8):2483-5. PubMed ID: 23026625
[TBL] [Abstract][Full Text] [Related]
12. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation.
Wang CH; Chou NK; Ko WJ; Chi NH; Tsao CI; Wang SS
Transplant Proc; 2008 Oct; 40(8):2600-2. PubMed ID: 18929812
[TBL] [Abstract][Full Text] [Related]
13. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation.
Franke GH; Trampenau C; Reimer J;
Transplant Proc; 2006 Jun; 38(5):1293-4. PubMed ID: 16797285
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience.
Pham SM; Kormos RL; Kawai A; Murali S; Hattler BG; Demetris AJ; Griffith BP
Transplant Proc; 1996 Apr; 28(2):1002-4. PubMed ID: 8623208
[No Abstract] [Full Text] [Related]
15. Replacement of cyclosporine by tacrolimus for immunosuppression in heart transplant patients: safety and efficacy.
Crespo-Leiro MG; Paniagua MJ; Mosquera I; Tabuyo T; De la Fuente L; Bouzas B; Rodriguez JA; Hermida LF; Juffé A; Castro-Beiras A
Transplant Proc; 2002 Feb; 34(1):113-4. PubMed ID: 11959213
[No Abstract] [Full Text] [Related]
16. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study.
Pacor ML; Di Lorenzo G; Martinelli N; Mansueto P; Rini GB; Corrocher R
Clin Exp Allergy; 2004 Apr; 34(4):639-45. PubMed ID: 15080819
[TBL] [Abstract][Full Text] [Related]
17. Conversion to Neoral for tacrolimus-related adverse effects in liver transplant recipients and improvement in quality of life.
Tolba RH; Wrigge B; Machein U; Minor T; Kalff JC; Hirner A; Wolff M
Transplant Proc; 2001; 33(7-8):3446-7. PubMed ID: 11750475
[No Abstract] [Full Text] [Related]
18. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up?
Groetzner J; Meiser BM; Schirmer J; Koglin J; vScheidt W; Klauss V; Cremer P; Reichenspurner H; Reichart B
Transplant Proc; 2001; 33(1-2):1461-4. PubMed ID: 11267373
[No Abstract] [Full Text] [Related]
19. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients.
Israni A; Brozena S; Pankewycz O; Grossman R; Bloom R
Am J Kidney Dis; 2002 Mar; 39(3):E16. PubMed ID: 11877596
[TBL] [Abstract][Full Text] [Related]
20. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
